Ann: Results of LCT Parkinsons trial require further analysis, page-22

The problem is this. The treated patients as a group did no better than the placebo control patients- even at 26 weeks. If anything the highest doseage group did worse. Thats an outright failure of the trial efficacy, and the reason its necessary to do placebo controls so we don't get fooled. Of interest the best performing group by far appears to be the one with the lowest dose.

However, trials have been regarded as failures at the trial endpoints because the evaluation was concluded too soon, since neurones grow slowly. The other possibility is that some subgroups of patients might have done better than others. With small study numbers a few refractory patients can have a large effect and mask the efficacy of the treatment.

But without a doubt there will be no application for commercial treatment and funding will be difficult to obtain